Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jun;17(6):392-7.
doi: 10.1089/dia.2014.0278. Epub 2015 Mar 3.

Glycemic Variability Is Associated with Frequency of Blood Glucose Testing and Bolus: Post Hoc Analysis Results from the ProAct Study

Affiliations
Clinical Trial

Glycemic Variability Is Associated with Frequency of Blood Glucose Testing and Bolus: Post Hoc Analysis Results from the ProAct Study

Andreas Pfützner et al. Diabetes Technol Ther. 2015 Jun.

Abstract

Introduction: The ProAct study has shown that a pump switch to the Accu-Chek(®) Combo system (Roche Diagnostics Deutschland GmbH, Mannheim, Germany) in type 1 diabetes patients results in stable glycemic control with significant improvements in glycated hemoglobin (HbA1c) in patients with unsatisfactory baseline HbA1c and shorter pump usage time.

Patients and methods: In this post hoc analysis of the ProAct database, we investigated the glycemic control and glycemic variability at baseline by determination of several established parameters and scores (HbA1c, hypoglycemia frequency, J-score, Hypoglycemia and Hyperglycemia Indexes, and Index of Glycemic Control) in participants with different daily bolus and blood glucose measurement frequencies (less than four day, four or five per day, and more than five per day, in both cases). The data were derived from up to 299 patients (172 females, 127 males; age [mean±SD], 39.4±15.2 years; pump treatment duration, 7.0±5.2 years).

Results: Participants with frequent glucose readings had better glycemic control than those with few readings (more than five readings per day vs. less than four readings per day: HbA1c, 7.2±1.1% vs. 8.0±0.9%; mean daily blood glucose, 151±22 mg/dL vs. 176±30 mg/dL; percentage of readings per month >300 mg/dL, 10±4% vs. 14±5%; percentage of readings in target range [80-180 mg/dL], 59% vs. 48% [P<0.05 in all cases]) and had a lower glycemic variability (J-score, 49±13 vs. 71±25 [P<0.05]; Hyperglycemia Index, 0.9±0.5 vs. 1.9±1.2 [P<0.05]; Index of Glycemic Control, 1.9±0.8 vs. 3.1±1.6 [P<0.05]; Hypoglycemia Index, 0.9±0.8 vs. 1.2±1.3 [not significant]). Frequent self-monitoring of blood glucose was associated with a higher number of bolus applications (6.1±2.2 boluses/day vs. 4.5±2.0 boluses/day [P<0.05]). Therefore, a similar but less pronounced effect on glycemic variability in favor of more daily bolus applications was observed (more than five vs. less than four bolues per day: J-score, 57±17 vs. 63±25 [not significant]; Hypoglycemia Index, 1.0±1.0 vs. 1.5±1.4 [P<0.05]; Hyperglycemia Index, 1.3±0.6 vs. 1.6±1.1 [not significant]; Index of Glycemic Control, 2.3±1.1 vs. 3.1±1.7 [P<0.05]).

Conclusions: Pump users who perform frequent daily glucose readings have a better glycemic control with lower glycemic variability.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>
FIG. 1.
Distribution according to the frequency of daily glucose measurements and mean daily insulin bolus.
<b>FIG. 2.</b>
FIG. 2.
Reduction of glycemic variability by more frequent glucose tests versus the low frequency test group: Low Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI), Glycemic Risk Assessment Diabetes Equation (GRADE), Hypoglycemia Index (HypoIndex), Hyperglycemia Index (HyperIndex), and Index of Glycemic Control (IGC). Results are normalized to 100% for the low frequency test group.

References

    1. Pickup JC: Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012;366:1616–1624 - PubMed
    1. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779–1784 - PubMed
    1. Paul N, Kohno T, Klonoff DC: A review of the security of insulin pump infusion systems. J Diabetes Sci Technol 2011;5:1557–1562 - PMC - PubMed
    1. Didangelos T, Iliadis F: Insulin pump therapy in adults. Diabetes Res Clin Pract 2011;93(Suppl 1):S109–S113 - PubMed
    1. Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group: Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-Nations Trial. Diabet Med 2006;23:141–147 - PubMed

Publication types

MeSH terms

LinkOut - more resources